1. Terry J. Rosen: CEO, Managing Director at Arcus Ventures, LLC.
2. Peter Barton Hutt: Senior Counsel, Former Partner at the Covington & Burling law firm.
3. Ross C. Haghighat: CEO of Elixir Pharmaceuticals and Board of Advisors, University of California, San Francisco, Entrepreneurship Center.
4. Laura Brege: General Partner at Cervantes Life Science Partners LLC, Member of the Board of Directors of Five Prime Therapeutics, Endocyte, and Aimmune Therapeutics.
5. Reinhard J. Ambros: Managing Director at MPM Capital LLC, Board of Directors of Tizona Therapeutics, Cambridge Cancer Genomics, and Cullinan Therapeutics.
6. Troy Wilson: CEO of Kura Oncology and Director of the Board of Directors of Turning Point Therapeutics.
Denny Lanfear: Co-founder and CEO of Coherus Biosciences, Proteolix.
Executive Management:
1. Terry Rosen: CEO and Director.
2. Juan C. Jaen: Chief Scientific Officer and Co-Founder.
3. Jennifer Jarrett: CFO and Executive VP.
4. Eric Hoefer: General Counsel and Executive VP.
5. David Johnson: Senior VP of Business Development.
6. Bill Grossman: Senior VP of Clinical Development.
Katherine Soo: Senior VP of Regulatory Affairs.
These are the biographies of some of the directors and executive management members of Arcus Biosciences, Inc. Terry J. Rosen: CEO, Managing Director at Arcus Ventures, LLC.
2. Peter Barton Hutt: Senior Counsel, Former Partner at the Covington & Burling law firm.
3. Ross C. Haghighat: CEO of Elixir Pharmaceuticals and Board of Advisors, University of California, San Francisco, Entrepreneurship Center.
4. Laura Brege: General Partner at Cervantes Life Science Partners LLC, Member of the Board of Directors of Five Prime Therapeutics, Endocyte, and Aimmune Therapeutics.
5. Reinhard J. Ambros: Managing Director at MPM Capital LLC, Board of Directors of Tizona Therapeutics, Cambridge Cancer Genomics, and Cullinan Therapeutics.
6. Troy Wilson: CEO of Kura Oncology and Director of the Board of Directors of Turning Point Therapeutics.
Denny Lanfear: Co-founder and CEO of Coherus Biosciences, Proteolix.
Executive Management:
1. Terry Rosen: CEO and Director.
2. Juan C. Jaen: Chief Scientific Officer and Co-Founder.
3. Jennifer Jarrett: CFO and Executive VP.
4. Eric Hoefer: General Counsel and Executive VP.
5. David Johnson: Senior VP of Business Development.
6. Bill Grossman: Senior VP of Clinical Development.
Katherine Soo: Senior VP of Regulatory Affairs.
These are the biographies of some of the directors and executive management members of Arcus Biosciences, Inc. Terry J. Rosen: CEO, Managing Director at Arcus Ventures, LLC.
2. Peter Barton Hutt: Senior Counsel, Former Partner at the Covington & Burling law firm.
3. Ross C. Haghighat: CEO of Elixir Pharmaceuticals and Board of Advisors, University of California, San Francisco, Entrepreneurship Center.
4. Laura Brege: General Partner at Cervantes Life Science Partners LLC, Member of the Board of Directors of Five Prime Therapeutics, Endocyte, and Aimmune Therapeutics.
5. Reinhard J. Ambros: Managing Director at MPM Capital LLC, Board of Directors of Tizona Therapeutics, Cambridge Cancer Genomics, and Cullinan Therapeutics.
6. Troy Wilson: CEO of Kura Oncology and Director of the Board of Directors of Turning Point Therapeutics.
Denny Lanfear: Co-founder and CEO of Coherus Biosciences, Proteolix.
Executive Management:
1. Terry Rosen: CEO and Director.
2. Juan C. Jaen: Chief Scientific Officer and Co-Founder.
3. Jennifer Jarrett: CFO and Executive VP.
4. Eric Hoefer: General Counsel and Executive VP.
5. David Johnson: Senior VP of Business Development.
6. Bill Grossman: Senior VP of Clinical Development.
Katherine Soo: Senior VP of Regulatory Affairs.
These are the biographies of some of the directors and executive management members of Arcus Biosciences, Inc. Terry J. Rosen: CEO, Managing Director at Arcus Ventures, LLC.
2. Peter Barton Hutt: Senior Counsel, Former Partner at the Covington & Burling law firm.
3. Ross C. Haghighat: CEO of Elixir Pharmaceuticals and Board of Advisors, University of California, San Francisco, Entrepreneurship Center.
4. Laura Brege: General Partner at Cervantes Life Science Partners LLC, Member of the Board of Directors of Five Prime Therapeutics, Endocyte, and Aimmune Therapeutics.
5. Reinhard J. Ambros: Managing Director at MPM Capital LLC, Board of Directors of Tizona Therapeutics, Cambridge Cancer Genomics, and Cullinan Therapeutics.
6. Troy Wilson: CEO of Kura Oncology and Director of the Board of Directors of Turning Point Therapeutics.
Denny Lanfear: Co-founder and CEO of Coherus Biosciences, Proteolix.
Executive Management:
1. Terry Rosen: CEO and Director.
2. Juan C. Jaen: Chief Scientific Officer and Co-Founder.
3. Jennifer Jarrett: CFO and Executive VP.
4. Eric Hoefer: General Counsel and Executive VP.
5. David Johnson: Senior VP of Business Development.
6. Bill Grossman: Senior VP of Clinical Development.
Katherine Soo: Senior VP of Regulatory Affairs.
These are the biographies of some of the directors and executive management members of Arcus Biosciences, Inc.
Arcus Biosciences Inc currently has 601 employees.
News about Arcus Biosciences Inc Key Personnel |
Investigative Arcus Biosciences Grants Stock Options to New Employees to Attract Top Talent
Hayward, Calif. - Arcus Biosciences, a clinical-stage biopharmaceutical company dedicated to developing innovative cancer treatments, has recently announced the grant of stock options to four new employees. This move comes in line with the company s mission to attract and retain top talent to further enhance its portfolio of groundbreaking molecules and combination therapies. With a strong focus on improving outcomes for cancer patients, Arcus Biosciences continues to make significant strides in the field of oncology.
The Compensation Committee of Arcus Biosciences Board of Directors has approved these stock...
|
